Oramed announced the formation of a 50/50 joint venture between Genomma Lab (www.genommalab.com/en/) and Oramed’s majority-owned subsidiary Oravax Medical Inc. (www.ora-vax.com) to develop and commercialize Oravax’s oral COVID-19 vaccine candidate in Mexico.
Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma
Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021, at 11:00 am EST.
To view the press event: https://us02web.zoom.us/webinar/register/WN_QTGUI13dTdmWdUFKrg_Tbg
